Plain-English translation of NCT07391813 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new medication called to see if it can help people with advanced small cell lung cancer — a type of lung cancer that has either spread to other parts of the body or cannot be removed with surgery. Researchers want to find out if this medication is safe, what side effects it might cause, and whether it can help shrink or control the cancer in people whose cancer has already progressed despite standard chemotherapy treatment.
Small cell lung cancer is an aggressive cancer, and many patients find that standard chemotherapy stops working over time. This trial exists to find new treatment options for people in this situation — patients who need better ways to control their cancer when their cancer has already stopped responding to conventional therapy.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the study medication through an IV (intravenous infusion) twice per treatment cycle — on day 1 and day 15 — with each cycle lasting 28 days. Throughout your participation, you'll have regular check-ins with the study doctor to monitor how you're feeling, any side effects you may experience, and how your cancer is responding to treatment. The study team will ask you about your health, any new symptoms, and any other medications you're taking.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Serbia